Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
Lymphokine activated killer (LAK) cells have been shown to exert a potent cytotoxic effect on many histologically different tumors and virally infected targets. Most normal cells but very few tumors have proven resistant to LAK lysis. The availability of two LAK resistant tumors, P815r, a murine mastocytoma, and SNUC-1, a human colon carcinoma, allowed us to study the phenomenon of LAK lysis. We examined the role of surface molecules on targets, which mediate binding to LAK cells, by cold target competition experiments and lectin dependent cellular cytotoxicity assays. The results showed that in the murine system, P815r cells do not compete for lysis of the LAK sensitive target B16 whereas other LAK sensitive murine targets compete. Alternatively, in the human system, SNUC-1 cells compete for lysis of the LAK sensitive target SNUC-4 as do other LAK sensitive human tumor cells. Furthermore, inducing binding of target and effector cells with lectin reverted the resistance of P815r but not SNUC-1 targets to lysis by LAK cells. These results imply that distinct stages of the lytic pathway might be involved in the resistance of different tumors to killing by LAK cells. The murine cell line is resistant to lysis because it cannot bind LAK cells. The human target, which does bind LAK, was insensitive to the effects of tumor necrosis factor alpha (TNF-alpha), a lymphokine released by LAK effectors and possibly involved in their lysis. Resistance to TNF-alpha was not mediated by the presence of endogenous short-lived proteins in the SNUC-1 targets. The elucidation of mechanisms of resistance may provide a tool to improve current protocols of adoptive immunotherapy as well as insights as to how tumor cells are or are not killed by LAK effectors.
Bean
P
P
Department of Pathology, University of Southern California, Los Angeles.
Mazumder
A
A
D000818:Animals; D001667:Binding, Competitive; D002460:Cell Line; D003208:Concanavalin A; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D016650:Fluorescein-5-isothiocyanate; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D037102:Lectins / Q000494:pharmacology; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology*; D011975:Receptors, Mitogen / Q000032:analysis; D013154:Spleen; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D037102:Lectins; D011975:Receptors, Mitogen; D014409:Tumor Necrosis Factor-alpha; D003208:Concanavalin A; D016650:Fluorescein-5-isothiocyanate